This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Janssen-Cilag AB.
Reference
Hansson-Hedblom A, et al. Cost-effectiveness of ustekinumab in moderate to severe Crohn?s disease in Sweden Cost Effectiveness and Resource Allocation : 2 Aug 2018. Available from: URL: https://doi.org/10.1186/s12962-018-0114-y
Rights and permissions
About this article
Cite this article
Likely benefit of ustekinumab in Crohn's disease in Sweden. PharmacoEcon Outcomes News 810, 20 (2018). https://doi.org/10.1007/s40274-018-5211-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5211-9